## 21. Grants to third parties

21. Grants to third parties	esearch into prevention and causes 2016 £	Research into treatment 2016	Welfare 2016 £	Education 2016	Total 2016
Dr Maria Vinci, Institute of Cancer Research, The role of interclonal communication and the tumour					
microenvironment in driving paediatric GBM and DIPG migration and invasion	413,545				413,545
Dr Amin Hajitou, Imperial College London, Investigation of a harmless prokaryotic virus for intravenout argeting delivery of therapeutic nucleic acids to DIPG	JS	333,809			333,809
CLIC Sargent, To fund Paul's Fund, which provides much needed financial assistance to the families		333,009			333,009
of children being treated for cancer			332,596		332,596
Professor Giuseppe Battaglia, University College London, Precision delivery of chemotherapeutics			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		,,,,,,,
across the blood-brain barrier for treatment of brain tumours		327,500			327,500
Professor John Anderson, UCL Great Ormond Street Institute of Child Health, TCR-transduced T cell	lls				
for immunotherapy of paediatric high grade glioma		323,585			323,585
Dr Elizabeth Coyle, University of Nottingham, Convection enhanced delivery of N3-propargyl, a nove	el	050.045			050.045
analogue of temozolomide		258,845			258,845
Professor Chris Jones, Institute of Cancer Research, The role of histone H4K20 methylation in paediatric glioblastoma and DIPG	250 450				250 450
Professor Persis Amrolia, Great Ormond Street Hospital (via GOSH Children's Charity),	258,458				258,458
Immunotherapy with CD19 CAR redirected T cells for relapsed paediatric ALL (CARPALL).					
Extension of grant awarded in 2014		253,824			253,824
Professor Louis Chesler, The Institute of Cancer Research, Development of experimental models and	d	· · · · · · · · · · · · · · · · · · ·			
therapeutic strategies to target treatment-resistant, metastatic neuroblastoma		251,989			251,989
Dr Karin Straathof, UCL Great Ormond Street Institute of Child Health, Development of GD2-specific					
Bi-specific T-cell Engagers (BiTEs) for treatment of neuroblastoma		251,392			251,392
Dr Elizabeth Calton, Institute of Cancer Research, Mutational dynamics and their effect on			.=		.=
chemoresistance and metastasis in a genetically engineered model of relapsed neuroblastoma			250,000		250,000
Bristol Children's Hospital, 'Keeping Families Together', to provide family accommodation at Bristol Children's Hospital		250,000			250,000
Dr Katherine Clesham, UCL Great Ormond Street Institute of Child Health, Targeting c-MYB in		250,000			250,000
acute leukaemia through drug repositioning		249,999			249,999
Dr Marc Tischkowitz, University of Cambridge, Investigating microRNA processing genes in					
rhabdomyosarcomas and other DICER1-related childhood tumours	225,510				225,510
Dr Suzanne Turner, University of Cambridge, CRISPR-based genome-wide knockout and					
overexpression screens to identify acquired resistance mechanisms to ALK inhibition in neuroblaston		223,310			223,310
Professor David Walker, University of Nottingham, Children's Brain Tumour Drug Delivery Consortium				194,180	194,180
Together for Short Lives, To provide help for young people and their families with cancer to ensure the	at		400.000		100.000
they have the best quality care and support from the moment of diagnosis			180,000		180,000
Brainstrust, Expanding an effective brain tumour support service for children and their parents  Professor Ruth Jarrett, University of Glasgow, Evaluation of CCL17 as a diagnostic biomarker for			152,000		152,000
classical Hodgkin lymphoma		149,968			149,968
Professor Louis Chesler, The Institute of Cancer Research, Molecularly guided treatment in		140,000			140,000
childhood cancer		125,666			125,666
Lifelites, To help enhance the lives of children with cancer in hospices through the use of		,			
specialist technology			120,000		120,000
Dr Sarah Farndon, UCL Great Ormond Street Institute of Child Health, The developmental history of					
bilateral neuroblastoma	65,311				65,311
Professor Christine Harrison, Newcastle University, Sequencing the unsequenceable: development of					
ground-breaking technologies to investigate the role of complex genomic sequences in childhood car	ncer 55,022	40.000			55,022
Dr Helen Bryant, University of Sheffield, Novel therapies for MYCN-amplified neuroblastoma	rina	49,300			49,300
Dr Ian Carr, University of Leeds, Identification of MSH6 null individuals in patients suspected of suffer from Constitutional Mismatch Repair Cancer Syndrome	ing	31,587			31,587
Dr Mathuros Ruchirawat, Chulabhorn Research Institute, The 8th Princess Chulabhorn International		31,307			31,301
Science Congress	12,000				12,000
Professor David Walker, University of Nottingham, An international workshop to develop a web base					,
paediatric pre-operative cerebellar mutism risk stratification tool		10,000			10,000
Dr Rod Mitchell, University of Edinburgh, 1st UK Fertility Preservation Annual Meeting		8,975			8,975
Dr Ruman Rahman, University of Nottingham, Brain Tumour Initiative – Drug delivery development g	rant	5,000			5,000
Dr Evon Poon, Institute of Cancer Research, Advances in Neuroblastoma Research Congress 2016		2,120			2,120
Professor Terry Dwyer, University of Oxford, International Childhood Cancer Cohort Consortium (I4C					
Meeting 2016	1,000				1,000
Total grants to third parties	1,030,846	3,106,869	1,034,596	194,180	5,366,491